Weller M - Search Results

1

Defective p53 antiangiogenic signaling in glioblastoma.

Berger B, Capper D, Lemke D, Pfenning PN, Platten M, Weller M, von Deimling A, Wick W, Weiler M. Berger B, et al. Among authors: weller m. Neuro Oncol. 2010 Sep;12(9):894-907. doi: 10.1093/neuonc/noq051. Epub 2010 May 26. Neuro Oncol. 2010. PMID: 20504876 Free PMC article.

2

A new look at the role of p53 in leukemia cell sensitivity to chemotherapy.

Trepel M, Scheding S, Groscurth P, Horny HP, Malipiero U, Brugger W, Dichgans J, Weller M. Trepel M, et al. Among authors: weller m. Leukemia. 1997 Nov;11(11):1842-9. doi: 10.1038/sj.leu.2400824. Leukemia. 1997. PMID: 9369416

3

Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells.

Ständer M, Dichgans J, Weller M. Ständer M, et al. Among authors: weller m. J Neurooncol. 1998 May;37(3):191-8. doi: 10.1023/a:1005870122744. J Neurooncol. 1998. PMID: 9524077

4

New aspects of immunotherapy of leptomeningeal metastasis.

Herrlinger U, Weller M, Schabet M. Herrlinger U, et al. Among authors: weller m. J Neurooncol. 1998 Jun-Jul;38(2-3):233-9. doi: 10.1023/a:1005948722912. J Neurooncol. 1998. PMID: 9696377 Review.

5

Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.

Trepel M, Groscurth P, Malipiero U, Gulbins E, Dichgans J, Weller M. Trepel M, et al. Among authors: weller m. J Neurooncol. 1998 Aug;39(1):19-32. doi: 10.1023/a:1005910323338. J Neurooncol. 1998. PMID: 9760067

6

Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses.

Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, von Deimling A, Dichgans J. Weller M, et al. Int J Cancer. 1998 Dec 18;79(6):640-4. doi: 10.1002/(sici)1097-0215(19981218)79:6<640::aid-ijc15>3.0.co;2-z. Int J Cancer. 1998. PMID: 9842975

7

BCL-2 promotes migration and invasiveness of human glioma cells.

Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, Weller M. Wick W, et al. Among authors: weller m. FEBS Lett. 1998 Dec 4;440(3):419-24. doi: 10.1016/s0014-5793(98)01494-x. FEBS Lett. 1998. PMID: 9872414 Free article.

8

Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy?

Streffer JR, Schuster M, Zipp F, Weller M. Streffer JR, et al. Among authors: weller m. J Neurooncol. 1998 Dec;40(3):233-5. doi: 10.1023/a:1006173019048. J Neurooncol. 1998. PMID: 10066095

9

Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing.

Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M. Wick W, et al. Among authors: weller m. J Pharmacol Exp Ther. 1999 Jun;289(3):1306-12. J Pharmacol Exp Ther. 1999. PMID: 10336521

10

p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.

Pohl U, Wagenknecht B, Naumann U, Weller M. Pohl U, et al. Among authors: weller m. Cell Physiol Biochem. 1999;9(1):29-37. doi: 10.1159/000016300. Cell Physiol Biochem. 1999. PMID: 10352342

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,724 results

Search Page

Filters